Cash balance plan

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, November 13, 2023
Neurogranin, Plasma, CSF, PIN, Administration, Patient, Research, FDA, Caregiver, Pharmacology, Halozyme, ABOS, Cash balance plan, Clinical trial, R, Research and development, Biomarker, Pharmaceutical industry, Vaccine, Cryptocurrency, G&A, Acumen

ET

Key Points: 
  • ET
    CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2023 and provided a business update.
  • “We have also observed encouraging trends in CSF biomarker data from our Phase 1 study, further solidifying the pharmacology of ACU193.
  • In October 2023, the Company met with the FDA to discuss the next clinical trial in the development program for ACU193.
  • Acumen will host a conference call and live audio webcast today, Nov. 13, 2023, at 8:00 a.m.

Check Point Software Reports 2023 Third Quarter Financial Results

Retrieved on: 
Monday, October 30, 2023
SSE, Security Service, SASE, Check Point, Conference, Perimeter 81, GAAP, Acquisition, Cash balance plan, Tax, Security, Webcast, SAN, Software as a service, Video game, Cryptocurrency, Bank

SAN CARLOS, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN CARLOS, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the third quarter ended September 30, 2023.
  • We achieved total revenues near the top of our forecast range, with earnings per share hitting the peak,” stated Gil Shwed, Founder and CEO of Check Point Software.
  • Financial Highlights for the Third Quarter of 2023:
    Total Revenues: $596 million compared to $578 million in the third quarter of 2022, a 3 percent increase year over year.
  • GAAP Operating Income: $226 million compared to $221 million in the third quarter of 2022, representing 38 percent of revenues in the third quarter of 2023 and 2022, respectively.

Soluna Project Dorothy 1 Reaches Full Capacity of 50 MW, Company hits 2.6 EH/s Hashrate Milestone

Retrieved on: 
Tuesday, September 26, 2023
Hardware, Alternative Energy, Data Management, Green Technology, Energy, Sustainability, Technology, Environment, Artificial Intelligence, Other Technology, Telecommunications, Software, Networks, Other Energy, Internet, Utilities, Bitcoin, GAAP, Kilowatt-hour, PUE, EBITDA, Corporation, AMA, Communication, Project, Cash balance plan, Women Deliver, Cryptocurrency, Renewable energy, Bookkeeping

John Belizaire, CEO of Soluna Holdings, commented, “We’ve had a busy summer ramping Project Dorothy through record high temperatures.

Key Points: 
  • John Belizaire, CEO of Soluna Holdings, commented, “We’ve had a busy summer ramping Project Dorothy through record high temperatures.
  • As we approach the peak wind months and cooler temperatures in Texas, we have achieved a key milestone to complete Project Dorothy 1 and bring it to its 50 MW capacity.
  • We have also made great progress accelerating development at Project Dorothy 2, Project Kati, and working on operational improvements, including significant reductions in SG&A.
  • Curtailment Consumption Ramps – Soluna has now monetized a groundbreaking 1,286 MWh of curtailed (wasted) energy for its Power Partner at Project Dorothy.

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, August 8, 2023
ABOS, Therapeutic index, Cash balance plan, Brain, PIN, Patient, Administration, Research and development, R, Research, FDA, Conference, Cryptocurrency, Pharmaceutical industry, Acumen, G&A

ET

Key Points: 
  • ET
    CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the second quarter of 2023 and provided a business update.
  • “We are well-capitalized and expect our runway to support current operational and clinical activities into the second half of 2026.
  • In the fourth quarter of 2023, the Company anticipates an interaction with the FDA to discuss future clinical development plans.
  • Acumen will host a conference call and live audio webcast today, August 8, 2023, at 8:00 a.m.

Check Point Software Reports Over 22% Eps Growth in the Second Quarter

Retrieved on: 
Wednesday, July 26, 2023
Tax, Cash balance plan, GAAP, SAN, Infinity, Webcast, Growth, EPS, Security, Conference, Cryptocurrency, Video game, Bank

SAN CARLOS, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SAN CARLOS, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the second quarter ended June 30, 2023.
  • “The second quarter delivered robust profitability with over 22 percent growth in EPS.
  • Financial Highlights for the Second Quarter of 2023:
    Total Revenues:$589 million compared to $571 million in the second quarter of 2022, a 3 percent increase year over year.
  • GAAP Operating Income: $221 million compared to $209 million in the second quarter of 2022, representing 38 percent and 37 percent of total revenues in the second quarter of 2023 and 2022, respectively.

Wolters Kluwer announces Cycle 3 Defined Benefit and Cash Balance plan restatement documents on ftwilliam.com

Retrieved on: 
Monday, July 17, 2023
Insurance, IRC, IRS, Cash balance plan, Wolters Kluwer, Language, Solar cycle 3, PDS, PPA, Death, Software, Life insurance

NEW YORK, July 17, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced that ftwilliam.com, the leading provider of software and services to retirement plan service providers, has made its Cycle 3 Defined Benefit and Cash Balance retirement plan documents available to customers.

Key Points: 
  • NEW YORK, July 17, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced that ftwilliam.com , the leading provider of software and services to retirement plan service providers, has made its Cycle 3 Defined Benefit and Cash Balance retirement plan documents available to customers.
  • The Cycle 3 Defined Benefit and Cash Balance plan documents available on ftwilliam.com include an IRC 401(a)(26) failsafe provision that automatically minimizes the cost of compliance to the lowest dollar amount possible.
  • Retirement plan service providers who are not currently using ftwilliam.com for Defined Benefit or Cash Balance documents can convert their current PPA plans over to the new Cycle 3 documents and take advantage of the integration between the software's document module and Defined Benefit Compliance software for 2023 administration.
  • The IRS window for the pre-approved Defined Benefit and Cash Balance plans runs through March 31, 2025.

MindMed Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 4, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, GAD, Intellectual property, Anticipation, Medicine, Spectrum, Autism spectrum, Telephone, Clinical trial, ADHD, Cash balance plan, Pharmacokinetics, University Hospital of Basel, G&A, Attention deficit hyperactivity disorder predominantly inattentive, ASCP, Research and development, DSM-IV codes, MDD, Patient, Patent, ASD, Vital signs, UHB, Administration, Annual general meeting, Webcast, Society, Conference, NEO, Safety, MindMed, Finance, Pharmaceutical industry, Cryptocurrency, Fine chemical, R

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.
  • The Company plans to host an analyst and investor day in the second quarter of 2023.
  • G&A expenses were $8.3 million for the quarter ended March 31, 2023, compared to $8.3 million for the quarter ended March 31, 2022.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s first quarter 2023 financial results.

Check Point Software Technologies Reports 2023 First Quarter Financial Results

Retrieved on: 
Monday, May 1, 2023
Tax, Cash balance plan, Check Point, GAAP, SAN, Infinity, Webcast, Growth, EPS, Earnings, Security, Cryptocurrency, Video game, Bank

SAN CARLOS, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the quarter ended March 31st, 2023.

Key Points: 
  • SAN CARLOS, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP), today announced its financial results for the quarter ended March 31st, 2023.
  • “We are pleased to report good financial results with 15 percent growth in non-GAAP EPS and 13 percent growth in security subscription revenues.
  • The economic slowdown has resulted in extended product sales cycles, while recurring revenues were healthy and reached over 80 percent of total revenues for the first time.” said Gil Shwed, Founder & CEO of Check Point Software Technologies.
  • GAAP Operating Income: $200 million same as in the first quarter of 2022, representing 35 percent and 37 percent of total revenues in the first quarter of 2023 and 2022, respectively.

MSCI Reports Financial Results for First Quarter 2023

Retrieved on: 
Tuesday, April 25, 2023
Fintech, Professional Services, Finance, Climate, RCA, Uncertainty, Result, Share repurchase, Cash balance plan, Financial condition report, Real assets, MSCI, EBITDA, Annual report, Analysis, Growth, Total, Bank, Security (finance)

MSCI typically seeks to maintain minimum cash balances globally of approximately $225.0 million to $275.0 million for general operating purposes.

Key Points: 
  • MSCI typically seeks to maintain minimum cash balances globally of approximately $225.0 million to $275.0 million for general operating purposes.
  • Share Count and Share Repurchases: Weighted average diluted shares outstanding were 80.5 million in first quarter 2023, down 2.2% year-over-year.
  • Dividends: Approximately $110.5 million in dividends were paid to shareholders in first quarter 2023.
  • On April 24, 2023, the MSCI Board of Directors declared a cash dividend of $1.38 per share for second quarter 2023, payable on May 31, 2023 to shareholders of record as of the close of trading on May 12, 2023.

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

Retrieved on: 
Monday, March 27, 2023
ABOS, Amgen, Communication, Drug development, Marketing, CMC, Clinical trial, Cash balance plan, Fast Track, G&A, Cerebrospinal fluid, Accounting, MS, Plasma, PIN, Patient, AbbVie, Administration, JD, Research and development, R, Research, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Cryptocurrency, Acumen, Chemistry

In February 2023, enrollment was completed in the Company’s Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease.

Key Points: 
  • In February 2023, enrollment was completed in the Company’s Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease.
  • Acumen anticipates reporting topline results from this trial, including safety and proof-of-mechanism data, in the third quarter of 2023.
  • In 2022, we continued to expand our team with talent necessary to advance our mission to develop a novel treatment for AD.
  • Net loss for the year ended December 31, 2022 was $42.9 million, compared to a net loss of $100.6 million for the year ended December 31, 2021.